Dupilumab for Atopic Dermatitis: The Silver Bullet We Have Been Searching for?
Open Access
- 6 April 2020
- journal article
- review article
- Published by Springer Nature in Cureus
- Vol. 12 (4) , e7565
Abstract
Atopic dermatitis is a chronic inflammatory condition of the skin affecting a large number of people worldwide. Historically, this condition has been managed by topical corticosteroids and general skincare measures. The inadequacy of these management strategies has always driven efforts to find better drugs. Dupilumab has been recently approved for the management of atopic dermatitis. It is a human monoclonal antibody that inhibits the binding of key interleukins involved in the pathogenesis of atopic dermatitis, thus blocking the signaling mechanisms and disrupting the disease progression. Dupilumab reduces the severity and associated symptoms of atopic dermatitis. It improves the life quality of patients and reduces the anxiety associated with the disease. Combination therapy of dupilumab and topical corticosteroids is more effective than dupilumab monotherapy. The treatment-related adverse events include headache, injection site reaction, conjunctivitis, nasopharyngitis, and herpes viral infections. Moreover, the simultaneous use of live vaccines with dupilumab is contraindicated. It is also beneficial in the management of asthma, chronic rhinosinusitis, and eosinophilic esophagitis. In this review, we have discussed the clinical efficacy and safety profile of dupilumab in the management of atopic dermatitis.Keywords
This publication has 31 references indexed in Scilit:
- Assessing the severity of atopic dermatitis in clinical trials and practiceClinics in Dermatology, 2018
- Dupilumab: A New Paradigm for the Treatment of Allergic DiseasesJournal of Investigational Allergology and Clinical Immunology, 2018
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trialThe Lancet, 2017
- Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)Journal of the American Academy of Dermatology, 2016
- Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitisJournal of Allergy and Clinical Immunology, 2014
- Dupilumab Treatment in Adults with Moderate-to-Severe Atopic DermatitisNew England Journal of Medicine, 2014
- Adult eczema prevalence and associations with asthma and other health and demographic factors: A US population–based studyJournal of Allergy and Clinical Immunology, 2013
- Skin Barrier Disruption: A Requirement for Allergen Sensitization?Journal of Investigative Dermatology, 2012
- Cytokine Milieu of Atopic Dermatitis, as Compared to Psoriasis, Skin Prevents Induction of Innate Immune Response GenesThe Journal of Immunology, 2003
- Outcome Measures of Disease Severity in Atopic EczemaArchives of Dermatology, 2000